Phase III studies for new uses of Celgene's Revlimid in multiple myeloma meet endpoints
This article was originally published in Scrip
Executive Summary
Two recent Phase III trials of Celgene's Revlimid (lenalidomide) have examined the potential for maintenance use of the drug in previously treated patients, while others have examined its use in newly diagnosed multiple myeloma (MM) patients, possibly paving the way for new uses for the drug.